ScoreHaematology
MALT lymphoma prognostic index (MALT-IPI)
Estimates the risk of events in extranodal marginal zone (MALT) lymphoma using three clinical variables.
Updated 31 October 2026
When to use it
Patients with gastric or non-gastric MALT lymphoma who are candidates for systemic therapy, to stratify prognosis.
What it needs
- Age ≥ 70 years
- Ann Arbor stage III or IV
- LDH above the upper limit of normal
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Low risk: 5-year EFS ≈ 70 % |
| 1 | Intermediate risk: 5-year EFS ≈ 56 % |
| ≥ 2 | High risk: 5-year EFS ≈ 29 % |
Practical tip
It was developed in the IELSG-19 trial (chlorambucil, rituximab or both) and validated in independent cohorts; it discriminates in both gastric and non-gastric MALT.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
